Tirzepatide 10mg
Tirzepatide is a dual GIP and GLP-1 receptor agonist research peptide. This novel dual-incretin compound has been extensively studied in metabolic research applications involving glucose uptake and energy expenditure pathways.
≥99%
10mg
Lyophilized Powder
Store at -20°C. Protect from light and moisture.
Mechanism of Action
Tirzepatide is an acylated 39-amino-acid peptide engineered to simultaneously activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. By binding both incretin receptors, it enhances insulin secretion in a glucose-dependent manner while suppressing glucagon release, slowing gastric emptying, and modulating appetite-regulating pathways in the hypothalamus.
Research Overview
Tirzepatide represents a novel class of dual-incretin receptor agonists that has been extensively studied in the SURPASS and SURMOUNT clinical trial programs. These trials have demonstrated significant effects on glycemic control and body weight reduction in research subjects with type 2 diabetes and obesity.
In the landmark SURMOUNT-1 trial, tirzepatide demonstrated dose-dependent reductions in body weight of 15–20.9% compared to placebo over 72 weeks, establishing it as one of the most effective compounds studied for metabolic research. The dual-agonist mechanism is hypothesized to produce synergistic effects beyond what either GIP or GLP-1 receptor activation achieves alone.
Research has also explored tirzepatide's effects on cardiovascular risk factors, hepatic steatosis, and insulin resistance. The SELECT trial and SURPASS-CVOT are investigating outcomes in cardiovascular disease contexts, while emerging data from studies on metabolic dysfunction-associated steatotic liver disease (MASLD) show promising reductions in liver fat content.
Published Research
Comprehensive review establishing tirzepatide as a first-in-class dual GIP/GLP-1 receptor co-agonist with superior glycemic and weight reduction effects. Cited by 382+ studies.
Tirzepatide is a synthetic 39-amino-acid peptide based on the native GIP sequence, demonstrating dose-dependent improvements in HbA1c and body weight across Phase 2/3 trials. Cited by 331+ studies.
Reference-level overview covering pharmacology, mechanism, clinical trial data, and research applications of tirzepatide as a dual GIP/GLP-1 agonist.
Chemical Profile
| Sequence | Y[Aib]EGTFTSDVSSYLEG[Aib]AAKEFIAWLVKGRG (39 aa, C20 fatty diacid modification) |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular Weight | 4813.5 g/mol |
| CAS Number | 2023788-19-2 |
| Half-Life | ~5 days (due to albumin binding via C20 fatty diacid spacer) |
| Solubility | Soluble in sterile water or bacteriostatic water; pH-dependent solubility |
| Bioavailability | High subcutaneous bioavailability (~80%) due to albumin binding and acylation |
Research Applications
References & Further Reading
- Tirzepatide — Wikipedia— Wikipedia
- Tirzepatide Research — PubMed Search— PubMed
- ClinicalTrials.gov — Tirzepatide Studies— ClinicalTrials.gov
- Tirzepatide — DrugBank— DrugBank
Research Use Only
This product is intended solely for laboratory research, analytical testing, and educational purposes. NOT FOR HUMAN CONSUMPTION. NOT FOR MEDICAL, VETERINARY, OR DIAGNOSTIC USE. This product has not been evaluated by the FDA.
